Radical Numerics, a biotechnology company developing AI-generated DNA, raises $50 million in new funding to expand research aimed at “reinventing biology,” according to reports. The company’s approach focuses on modeling and designing entire biological systems rather than concentrating only on individual molecules. The funding is intended to support further development of the company’s platform and research efforts in areas including biodefense and AI-driven drug discovery. Reporting describes the company’s core thesis as leveraging AI to understand biological relationships at a systems level, which it says could improve how biological functions are predicted and engineered. The announcement frames the work as potentially applicable to responding to biological threats and accelerating the discovery and development of therapeutics. While sources highlight the company’s broader goals, they do not provide detailed clinical outcomes or specific product timelines in the available excerpt. Overall, the coverage is aligned on the fundraising amount and the company’s central strategy: using AI-generated DNA and systems-level biological understanding to guide future biodefense and drug discovery work.